Education
About Us
Working with TipRanks
Follow Us
HCA Healthcare (HCA)
NYSE:HCA
HCA Analyst Ratings
Moderate Buy
13 Buy
7 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HCA Stock 12 Month Forecast
Average Price Target
$477.26
▲(0.14% Upside)
| Highest Price Target$525.00 | Average Price Target$477.26 | Lowest Price Target$412.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
$420
Hold
-11.88%
Downside
Reiterated
11/05/25
Jefferies
$485→$525
Buy
10.15%
Upside
Reiterated
10/28/25
Truist Financial
$460→$495
Buy
3.86%
Upside
Reiterated
10/27/25
Mizuho Securities
$475→$505
Buy
5.96%
Upside
Reiterated
10/27/25
Oppenheimer
$400→$500
Buy
4.91%
Upside
Reiterated
10/27/25
UBS
$495→$525
Buy
10.15%
Upside
Reiterated
10/27/25
Goldman Sachs
$470→$520
Buy
9.10%
Upside
Reiterated
10/27/25
RBC Capital
$449→$482
Buy
1.13%
Upside
Reiterated
10/27/25
Cantor Fitzgerald
$444→$525
Buy
10.15%
Upside
Reiterated
10/27/25
Morgan Stanley
$400→$425
Hold
-10.83%
Downside
Reiterated
10/27/25
HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy UncertaintiesWe're modeling a slight y/y decline in EBITDA margin percentage in 2026 reflecting uncertainty around enhance subsidies and exchange volumes. Against an uncertain federal policy backdrop, the ability to further flex its resiliency program ($600-$800mn in targeted impact over 5 years beginning in 2023) is key. The company has seen a benefit to date (20.4% margin in 2025E, up from 19.6% in 2023) and management stressed on the call that the program is not static, with the company scaling initiatives across cost management, digital tools, and AI. Same facility equivalent admissions increased 2.4% Y/Y, led by Commercial +3.7% (Exchanges +8% and commercial excluding exchanges +2.4%), Medicare +3.4% (MA +4.8% and traditional +1.4%, while Self-Pay declined 6%.
KeyBanc
$465→$475
Buy
-0.34%
Downside
Reiterated
10/27/25
Guggenheim
―
Hold
―
Reiterated
10/27/25
Barclays
$445→$494
Buy
3.65%
Upside
Reiterated
10/27/25
TD Cowen
$380→$490
Buy
2.81%
Upside
Reiterated
10/27/25
HCA Healthcare: Strong Financial Performance and Strategic Growth Drive Buy RatingWe raise our PT to $490, ~10.4x our 2026E EBITDA, lower if FL/VA/GA SDPs are approved. The 3 preprints are submitted at or near ACR, and not modeled herein. Call Commentary - HCA reported 3Q25 revenue growth of +9.6% and adj EBITDA +18% yty. Growth was fueled by broad-based volume strength, payer mix benefits, higher acuity, and additional revenue from Medicaid SDPs. Operational outperformance drove $200m of the $450m FY25 adj EBITDA guidance raise with the remaining $250m from higher SDPs. SS admissions were +2.4%, with IP/OP surgical volumes and ER visits also posting growth. HCA’s diversified portfolio helped offset underperformance in certain regions, with one previously challenged division recovering and another still working through issues.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
$420
Hold
-11.88%
Downside
Reiterated
11/05/25
Jefferies
$485→$525
Buy
10.15%
Upside
Reiterated
10/28/25
Truist Financial
$460→$495
Buy
3.86%
Upside
Reiterated
10/27/25
Mizuho Securities
$475→$505
Buy
5.96%
Upside
Reiterated
10/27/25
Oppenheimer
$400→$500
Buy
4.91%
Upside
Reiterated
10/27/25
UBS
$495→$525
Buy
10.15%
Upside
Reiterated
10/27/25
Goldman Sachs
$470→$520
Buy
9.10%
Upside
Reiterated
10/27/25
RBC Capital
$449→$482
Buy
1.13%
Upside
Reiterated
10/27/25
Cantor Fitzgerald
$444→$525
Buy
10.15%
Upside
Reiterated
10/27/25
Morgan Stanley
$400→$425
Hold
-10.83%
Downside
Reiterated
10/27/25
HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy UncertaintiesWe're modeling a slight y/y decline in EBITDA margin percentage in 2026 reflecting uncertainty around enhance subsidies and exchange volumes. Against an uncertain federal policy backdrop, the ability to further flex its resiliency program ($600-$800mn in targeted impact over 5 years beginning in 2023) is key. The company has seen a benefit to date (20.4% margin in 2025E, up from 19.6% in 2023) and management stressed on the call that the program is not static, with the company scaling initiatives across cost management, digital tools, and AI. Same facility equivalent admissions increased 2.4% Y/Y, led by Commercial +3.7% (Exchanges +8% and commercial excluding exchanges +2.4%), Medicare +3.4% (MA +4.8% and traditional +1.4%, while Self-Pay declined 6%.
KeyBanc
$465→$475
Buy
-0.34%
Downside
Reiterated
10/27/25
Guggenheim
―
Hold
―
Reiterated
10/27/25
Barclays
$445→$494
Buy
3.65%
Upside
Reiterated
10/27/25
TD Cowen
$380→$490
Buy
2.81%
Upside
Reiterated
10/27/25
HCA Healthcare: Strong Financial Performance and Strategic Growth Drive Buy RatingWe raise our PT to $490, ~10.4x our 2026E EBITDA, lower if FL/VA/GA SDPs are approved. The 3 preprints are submitted at or near ACR, and not modeled herein. Call Commentary - HCA reported 3Q25 revenue growth of +9.6% and adj EBITDA +18% yty. Growth was fueled by broad-based volume strength, payer mix benefits, higher acuity, and additional revenue from Medicaid SDPs. Operational outperformance drove $200m of the $450m FY25 adj EBITDA guidance raise with the remaining $250m from higher SDPs. SS admissions were +2.4%, with IP/OP surgical volumes and ER visits also posting growth. HCA’s diversified portfolio helped offset underperformance in certain regions, with one previously challenged division recovering and another still working through issues.
Best Analysts Covering HCA Healthcare
1 Month
xxx
Success Rate
27/38 ratings generated profit
Average Return
+4.87%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.05% of your transactions generating a profit, with an average return of +4.87% per trade.
3 Months
xxx
Success Rate
23/30 ratings generated profit
Average Return
+9.84%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.67% of your transactions generating a profit, with an average return of +9.84% per trade.
1 Year
Success Rate
23/23 ratings generated profit
Average Return
+28.36%
reiterated a buy rating 13 days ago
Copying Ben Hendrix's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +28.36% per trade.
2 Years
xxx
Success Rate
46/46 ratings generated profit
Average Return
+54.58%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +54.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HCA Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
22
22
22
32
28
Hold
16
17
20
14
12
Sell
0
1
1
1
0
Strong Sell
0
0
0
0
0
total
38
40
43
47
40
Each month's total comprises the sum of three months' worth of ratings.
HCA Financial Forecast
HCA Stock Forecast FAQ
What is HCA’s average 12-month price target, according to analysts?
Based on analyst ratings, HCA Healthcare’s 12-month average price target is 477.26.
What is HCA’s upside potential, based on the analysts’ average price target?
HCA Healthcare has 0.14% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HCA a Buy, Sell or Hold?
HCA Healthcare has a consensus rating of Moderate Buy which is based on 13 buy ratings, 7 hold ratings and 0 sell ratings.
What is HCA Healthcare’s price target?
The average price target for HCA Healthcare is 477.26. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $525.00 ,the lowest forecast is $412.00. The average price target represents 0.14% Increase from the current price of $476.61.
The highest analyst price target is $525.00 ,the lowest forecast is $412.00. The average price target represents 0.14% Increase from the current price of $476.61.
What do analysts say about HCA Healthcare?
HCA Healthcare’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of HCA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.